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ABSTRACT 
The receptor for glucagon-like peptide 1 (GLP-1R) is a validated drug target for the treatment of 
type 2 diabetes and obesity. Recently the first three structures of GLP-1R were published ± an X-
ray structure of the apo transmembrane domain in the inactive conformation; an X-ray structure of 
the full-length receptor bound to a truncated peptide agonist; and a cryo-EM structure of the full-
length receptor bound with GLP-1 and coupled to the G protein Gs. Since the inactive structure 
was incomplete, and the two active-state structures shared significant differences, we utilised all 
available knowledge to build hybrid models of the full length active and inactive state receptors. 
The two models were simulated using molecular dynamics and the output trajectories analysed and 
compared to reveal insights into the mechanism for agonist-mediated receptor activation. His-7, 
Glu-9 and Asp-15 of GLP-1 act together to destabilise transmembrane helix 6 and extracellular 
loop 3 in order to generate an active conformation of GLP-1R. 
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INTRODUCTION 
Glucagon-like peptide-1 (GLP-1) is a hormone secreted by enteroendocrine L cells in response to 
feeding. It has multiple physiological effects, most notable of which are the potentiation of 
glucose-induced insulin secretion and the induction of satiety [reviewed in 1]. As such, the GLP-1 
receptor (GLP-1R) has been successfully targeted for anti-diabetic and anti-obesity therapy 
through the discovery of a number of peptidic GLP-1 analogues that have superior 
pharmacokinetic properties compared to those of the parent hormone [e.g. 2, 3]. Nevertheless, 
although there is emerging evidence for routes towards orally available peptide mimetics [4], they 
will require expensive dosing regimens, and there remains an unmet need for the development of 
commercially viable orally available non-peptidic drugs. In addition, the ability of GLP-1R to 
signal through both G-protein and G protein-independent pathways [5-7], opens up the possibility 
for new biased therapeutics that focus upon one particular pathway. However, in order to 
maximise the opportunities for rational discovery of such non-peptidic and/or biased agents, there 
is a requirement for a detailed understanding of how ligands bind and activate GLP-R 
 
 GLP-1R is a typical class B/secretin-family G protein-coupled receptor (GPCR) and as 
such is composed of two domains ± the N-terminal extracellular domain (NTD) comprising the 
first ~115 residues, and the transmembrane domain (TMD) comprising the remaining 7 
transmembrane helices and connecting regions. GLP-1 interacts with GLP-1R through a two-
domain mechanism in which the C-terminal half of the Į-helical ligand binds to the NTD, while 
the N-terminal half binds to the TMD [8, 9]. The latter interaction is critical for agonist-induced 
receptor activation and hence is the region of most interest when considering the discovery of 
novel GLP-1 agonists. Until recently, knowledge of the details of peptide-GLP-1R interactions 
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relied upon a large body of site-directed mutagenesis data (reviewed in [1]) coupled with 
molecular models that were derived from the isolated TMD structure of the glucagon receptor [10-
12]. Although useful, the inactive conformation of the glucagon receptor template used, alongside 
the absence of a TMD-bound peptide ligand, resulted in GLP-1/GLP-1R models that required a 
degree of interpretation and speculation. However, a step change in our knowledge of GLP-1R 
structure came with the simultaneous publication of three papers in mid-2017 which described 
GLP-1R in its inactive and active states [13-15]. 
The inactive structure of the TMD of GLP-1R was obtained through two structures (pdb 
codes 5VEW and 5VEX) of GLP-1R, each coupled with a different negative allosteric modulator 
which helped to stabilise the inactive conformation [13]. The crystallised receptor construct lacked 
the NTD and had a number of alterations from the wild type sequence. The active state of GLP-1R 
could be observed through two further molecular structures ± one being the cryo-EM structure of 
rabbit GLP-1R in complex with both Gs and GLP-1 (5VAI; 3.9Å resolution in region of interest; 
[14]), and the other being the X-ray crystal structure of a thermo-stabilised GLP-1R in complex 
with a non-natural C-truncated peptidic agonist (5NX2; [15]). The latter structure (5NX2) 
contained 11 stabilising mutations and displayed wild type-like agonist affinity but with reduced 
potency, suggesting a partially active conformation. The agonist was an 11-residue peptide based 
on the N-terminus of GLP-1, sharing five identical residues alongside several non-natural variants. 
Despite these differences, the resultant binding site correlated closely with the published site-
directed mutagenesis data. The cryo-EM structure (5VAI) described a 150 kDa complex that 
included GLP-1, the complete rabbit GLP-1R, and the Gs heterotrimeric G-protein stabilised by a 
nanobody (Nb35). This provided the first view of GLP-1R coupled to both its natural ligand and its 
primary G protein.  
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However, despite many similarities between the 5VAI and 5NX2 active GLP-1R 
structures, there remain a number of significant differences between these active state structures 
which impede a full understanding of agonist binding and activation (discussed below). Therefore, 
in order to fully understand how agonists bind and activate GLP-1R, we set out to build a high 
quality, complete, active-state, human GLP-1R model, docked with GLP-1, using a combination of 
both the 5VAI and 5NX2 structures as templates. This hybrid model was subjected to molecular 
dynamics simulations to refine the model and ascertain the dynamic details of the peptide-receptor 
interaction. A second objective was to generate a complete inactive wild type human GLP-1R 
model, by combining the inactive TMD of 5VEW with the empty NTD of 5NX2, and then to 
examine the stability of this model using molecular dynamics in order to compare the inactive 
conformation to that of the agonist-bound GLP-1R.  
 
MATERIALS AND METHODS 
All molecular model building manipulations were carried out using the tools embedded within 
PyMol (The PyMOL Molecular Graphics System, Version 1.7.2.3 Schrödinger, LLC.) unless 
otherwise stated.  
 
Building active GLP-1R (Supplementary Figure S1A). (i) 5VAI and 5NX2 were structurally 
aligned by superimposing the residues of their TMDs using the align function in PyMol. (ii) All 
residues in 5NX2 were deleted, apart from E139-K197 and E373-F393. (iii) The G-protein, 
nanobody, ligand and regions E139-K197 and E373-F393 were deleted from the 5VAI structure. 
(iv) The remaining atoms from both molecules were merged and saved to a single pdb file which 
was then used as a template to build a model of human GLP-1R using the homology modelling 
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server SWISS-MODEL [16; http://swissmodel.expasy.org/]. Residues Ser-129 to Glu-138, 
connecting the NTD and TMD, were built by SWISS-MODEL, as were any missing or altered side 
chains in the template. All other residues were built from the template and matched the starting 
conformations. The output pdb file from SWISS-MODEL represented the apo hybrid model of 
active human GLP-1R from Thr-29 to Arg-421. (v) GLP-DQGĮRI*s were added back into the 
model by structurally aligning the SWISS-MODEL output with 5VAI, extracting the co-ordinates 
for the GLP-DQGĮ (374-394) segments from 5VAI, and merging them with the active GLP-1R 
hybrid model.   
 
Building inactive GLP-1R (Supplementary Figure S1B). The NTD from 5NX2 represents the 
only apo structure of this domain and was hence selected as the NTD to fuse with the TMD from 
5VEW. (i) One monomer from the crystallographic dimer of 5VEW was deleted, as was the fusion 
partner. (ii) The remaining residues from 5VEW were structurally aligned with 5NX2 by 
superimposing the residues of their TMDs using the align function in PyMol. (iii) All residues in 
the TMD of 5NX2 were deleted, leaving only the NTD residues from Thr-29 to Glu-133 and also 
Met204 to Asp215 (the latter is the part of ECL1 which contacts the NTD on 5NX2 but is missing 
in 5NEW). (iv) The remaining atoms were merged and saved to a single pdb file. (v) This was 
used as a template to build a model of inactive human GLP-1R using SWISS-MODEL. All the 
missing regions in the template were built by SWISS-MODEL, as were all missing or mutated side 
chains. All other residues built from the template matched the starting conformations. The output 
represented the apo hybrid model of inactive human GLP-1R from Thr-29 to Arg-421. 
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Molecular Dynamics 
The starting models were first orientated with respect to the hydrocarbon core of the lipid bilayer 
utilising the OMP database and server [17]. The output pdb files were then used in the bilayer 
builder input generator of CHARMM-GUI [18]. The four disulphide bonds of GLP-1R were first 
defined and the models were then embedded into a 90 x 90 Å2 POPC bilayer membrane before a 
water/solvent box was added (TIP3P and 0.15 M NaCl). Simulations were all performed at 
303.15K temperature and 1 atm pressure, using Langevin dynamics with a damping coefficient of 
1/ps to control the temperature and a Nose-Hoover Langevin piston to control the pressure. A 
timestep of 2 fs was used, and Particle Mesh Ewald to account for long-range electrostatics.  A 
simple POPC bilayer has been used previously to simulate a model of GLP-1R [12] and indeed we 
found that this bilayer closely matched the boundaries predicted by OMP (see supplementary 
Figure S2). The models were subjected to equilibration (70 ns) and production (385-460 ns) using 
NAMD, a program developed by the Theoretical and Computational Biophysics Group in the 
Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-
Champaign [19]. Output trajectories were analysed using WORDOM and VMD [20, 21]. The 
simulation trajectory for the active hybrid model was analysed in detail between 280-370 ns using 
VMD in order to estimate the fraction of time in which all residue-residue hydrogen bonds were 
formed (defined as heavy atom distance of 3.5 Å or less, with an angle of 25° or less). A similar 
analysis was carried out for the inactive hybrid model trajectory between 200-380 ns. Example 
models in Figure 3 & 4 and in the Supplementary information are taken from the central frame of 
each of these two analysis windows (at 285 ns and 325 ns respectively for the active and inactive 
models). 
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RESULTS AND DISCUSSION 
Rationale for a hybrid GLP-1R model 
Despite many similarities between the TMD in the 5VAI and 5NX2 active GLP-1R 
structures, there are a number of differences that need to be resolved for a full understanding of 
agonist binding and activation mechanisms. While the relative positions of the NTD and TMD 
differ in the active 5VAI and 5NX2 structures, this is perhaps not surprising given the that 
flexibility between these domains in related receptors has been analysed and discussed previously 
[22]. Furthermore, since GLP-1 straddles the two domains in 5VAI, which limits their relative 
movement, the shorter 11-residue ligand in 5NX2 is bound to the TMD and is largely independent 
of NTD binding, hence enabling it more conformational flexibility between the domains. 
The most surprising difference between 5NX2 and 5VAI involves the conformation of 
TM6. While both structures display the expected outward movement of TM6 relative to that 
observed in the inactive 5VEW struFWXUH WR FUHDWH WKH UHTXLUHG ELQGLQJ VLWH IRU Į RI *s, the 
observed conformation and position of TM6 differs significantly in each active structure. TM6 in 
5VAI is highly distorted, non-linear and closely packed against the rest of the TM bundle in the 
central region (Figure 1A), in close agreement to that observed in the structure of the calcitonin 
receptor TMD in complex with Gs (Figure 1B; pdb code 5UZ7; [23]). However, TM6 in 5NX2 is 
much more regular and linear but is displaced away from the rest of the TM bundle such that there 
appears to be an unusual channel joining the extracellular peptide binding cavity to the 
intracellular space (Figure 1C). In our molecular dynamics simulations using 5NX2 without its 
ligand, the TM bundle fractured between TM5 and TM6 and allowed bilayer lipids to penetrate the 
receptor core (data not shown). Hence, given this 5NX2 instability, coupled with the good 
correlation between 5VAI and 5UZ7, and also that 5VAI represents a wild type GLP-1R sequence 
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coupled to GLP-1 and Gs, we elected to utile the TM6 conformation from 5VAI in our hybrid 
model. 
Nevertheless, there are some aspects of the 5VAI structure that appear to be less secure 
WKDQ 1;  ,Q SDUWLFXODU WKH &Į SRVLWLRQV RI $UJ-380 and Lys-288 at the extracellular end of 
TM7 are displaced by one helical turn between the two structures (Supplementary Figure S3). 
While in 2NX2 they interact with the ligand as expected from site-directed mutagenesis data and 
previous modelling studies (reviewed in [1]), in the 5VAI structure they point away from the TM 
bundle and would hence interact with the lipid head-group region of the bilayer. Given the known 
important role of Arg-380 and Lys-383 in peptide binding, we elected to take this region of TM7 
from 5NX2 when constructing the hybrid human GLP-1R model. As a consequence, we also took 
the contacting regions on TM1 and part of TM2 from 5NX2 in the hybrid model (Figures 2A and 
S1). While we believe such hybrid modelling represents the best approach (in the absence of 
reliable high-resolution structures) for creating a starting model for molecular dynamics 
simulations, there are likely to be a number approximations and associated errors in the model. For 
example, we must rely on SWISS-MODEL to accurately replace side chain conformations and to 
fill in missing gaps in the template primary structureLQFOXGLQJWKH³VWDON´ region linking the two 
domains. Furthermore, the newly created protein-protein interactions and the melding points 
between the different fragments used to create the hybrid models may result in less than optimal 
interactions and conformations, although we have used long relaxation times during the 
equilibration stages which should have fixed local inaccuracies. Nevertheless, it is important to 
interpret the output carefully in light of the mutagenesis and molecular pharmacological data in 
order to identify meaningful outcomes. 
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Simulations of hybrid active and inactive human GLP-1R models 
Due to the higher resolution of the single template structure used to build the TMD of the inactive 
model, relative to the two lower resolution structures used to build the active hybrid TMD, we 
expected the former to reach stability earlier in the MD simulations. Indeed, this was the case with 
a positional root mean square deviation (RMSD) relative to the starting model TMD plateauing at 
60 ns and remaining stable throughout the remainder of the 385 ns simulation (Figure 1C). The 
active hybrid model took longer to reach stability but nevertheless the RMSD plateaued after 230 
ns (Figure 2C).  
The principle difference between the inactive and active conformations of GPCRs is 
believed to be the outwards movement of the cytoplasmic half of TM6 away from the TM bundle 
in order to create the binding siWHIRUĮRIWKH*SURWHLQ[24]. Such a movement can be observed 
when comparing the inactive 5VEX and 5VEW structures with those of the active conformations 
5VAI and 5NX2 [13-15]. For example, the distance beWZHHQ WKH&Į DWRPVRI UHVLGXHV Arg-176 
(TM2) and Arg-348 (TM6) is 23.7 Å in 5NX2 and 25.3 Å in 5VAI, whereas it is only 12.1 Å in 
5VEW. These distances were maintained throughout the simulations of both our inactive and 
active models (Figure 2D). The outward movement of the cytoplasmic end of TM6 upon activation 
is accompanied by a large perturbation of the helix at Gly-361 and a movement of the segment of 
TM6 incorporating His-363 and Glu-364 towards the cytoplasmic side (&Įmovements of 6.2 Å 
and 4.4 Å respectively based on the starting models ± see Supplementary Figure S4). In addition, 
TM7 tilts towards TM6 at the extracellular end, with the hinge being at Gly-395, with an 
additional clockwise twist of the helix to move Arg-380 and Arg-383 from the exterior of the 
protein into the core of the receptor where they interact directly with the ligand (Figure 3). ECL3, 
which links the top of TM6 and TM7, undergoes a significant conformational rearrangement as a 
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result of these helical movements. The space created by the movement of TM7 towards TM6 is 
filled by the tilting of the extracellular side of TM1 around Gly-151. The final consequence is the 
outward movement of TM6 at the cytoplasmic end where the G protein docks. In our simulations, 
residues 382-UHJLRQRIWKHĮKHOL[RI*s remained stable and helical through the 460 ns active 
state simulation (Supplementary Figure S6G). 
In the inactive hybrid model, Arg-190 was able to remain hydrogen bonded with Gln-394 
for 40% of the trajectory (Figure 3A, blue). However, as can be seen, this interaction was 
abolished by ligand binding (Figure 3A, green) since Arg-190 (yellow) instead interacted with 
Glu-9* of the ligand (84%; GLP-1 residues will be identified with subscript * throughout). In 
addition, Glu-9* also interacts with the side chain hydroxyl groups of Tyr-148 and Tyr-152 (78% 
and 76% respectively), both residues that have been identified as being involved in GLP-1 
recognition (reviewed in [1]). The movement of Arg-190 to interact with Glu-9* results in Gln-394 
being free to move and interact with the exposed main chain carboxyl oxygen of Pro-358 of TM6, 
providing a helix cap for the cytoplasmic half of this helix following its disruption at Gly-361 
(Figure 3B). This represents a way in which agonist binding could stabilise one type of active state 
of GLP-1R. GLP-1 potency is sensitive to Arg-190 substitution, as is a synthetic variant of 
oxyntomodulin in which the native Gln at the third position was replaced by Glu [25]. Given that 
native oxyntomodulin (and synthetic Q9-GLP-1) can activate the cAMP pathway but are not 
sensitive to Arg-190 substitution [25], it is likely that they stabilise a different active state which 
does not rely upon direct Arg-190 binding or the breakage of the Arg-190/Gln-394 interaction. 
A second clear change in hydrogen bond formation resulting from ligand binding can be 
observed with Arg-380. In the inactive model, this residue forms a very stable hydrogen bond with 
Glu-373 throughout the trajectory (96%). Upon ligand binding, Arg-380 undergoes a significant 
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movement to interact with Asp-15* of the ligand (77%) (in agreement with mutagenesis data [1]), 
while the interaction with Glu-373 is also maintained (82%), albeit requiring a substantial 
conformational rearrangement of ECL3 (Figure 3D). Hence the movement of Arg-380 towards 
Asp-15* of the ligand encourages the rearrangement of ECL3, which is ultimately an essential 
requirement for the movement of TM6 and the creation of a Gs binding site. The position of Arg-
380 is conserved as a positively charged residue (Arg or Lys) in the receptors for glucagon, GLP-2 
and GIP, all of which also have a negatively charged residue (Asp or Glu) in the ligand at the 
position equivalent Asp-15* in GLP-1. Indeed, the oppositely charged residues have been 
interchanged from ligand to receptor in an elegant study by Moon et al. [27] showing a reciprocal 
rescue which strongly implicates the two residues in an interaction. In this study, Arg-380 was 
replaced by Asp, resulting in almost a 2000-fold reduction in potency. However, Arg9*-GLP-1, 
which had almost 100-fold lower potency at wild-type GLP-1R, was shown to have 120-fold 
improved potency at the Arg-380±Asp mutant receptor. 
A third arginine residue (Arg-299) also has substantially different interactions in the active 
and inactive model trajectories. Despite starting off pointing downwards towards the receptor core 
as in the 5VAI template, Arg-299 rapidly moved out of the binding pocket and then interacted with 
both Glu-294 (57%) and Glu-21* (40%) of the ligand (Supplementary Figure S6 A) as previously 
predicted from earlier mutagenesis and modelling studies [11]. Indeed, Arg-299 was placed in this 
external position in the 5NEX X-ray structure, adding further evidence towards this conformation 
in the active state. In the inactive model, Arg-299 forms a very stable interaction with both Glu-34 
(97%) on the NTD, and with Asp-372 (97%) of ECL2. Indeed, a characteristic of the active state is 
the close interaction between ECL2 and ECL3 ± for example, Glu-294, Asn-300 and Asn-304 
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interact with Asp-372 and Arg-376 (Supplementary Figure S6 B). This inter-loop interaction is 
absent in the active state.  
 
Ligand binding in active conformation.  
Glu-9* is clearly a critical residue, interacting with Arg-190 (84%), Tyr-148 (78%) and 
Tyr-152 (76%), and to a lesser extent with Thr-391 (16%). Likewise, Arg-380 is important since it 
interacts with Asp-15* (77%). Additional interactions are Thr-13* with Lys-297, and Glu-21* with 
Arg-299 ± both residues have been shown to be involved in agonist recognition [reviewed in 1]. 
However, the key residue for agonist-induced receptor activation in GLP-1R is the N-terminal His-
7*. In the early stages of the simulation, the positively charged N-terminal moiety interacted with 
Glu-9*, forming a four-way interaction with Arg-190 and Glu-364. However, this intra-ligand salt 
bridge eventually broke and consequently the distance between Arg-190 and Glu-264 increased. 
While Arg-190 continued to interact with Glu-9*, the N-terminal amine of His-7* interacted with 
both Glu-364* (78%) and Glu-387 (66%). It is interesting to note that, while there have been a 
number of mutations of these residues [reviewed in 1], it was only the double substitution by Yang 
et al. [28] which abolished ligand binding, suggesting that either of these Glu residues can partially 
compensate for the other in the less deleterious single mutations. The sharing of the interaction 
with the positively charged amino-terminus of GLP-1 by these two acidic side chains forms the 
centre of a network of salt bridges and hydrogen bonds involving several residues known to be 
critical for full agonist recognition (Asn-300, Trp-306, Arg-310, Asp-372, and Lys-383). It is 
interesting to note that Arg-310 and Lys-383 both directly stabilise Glu-364 and Glu-387, 
respectively, but display no direct interactions with GLP-1. This is in keeping with mutagenesis 
and pharmacological data which showed their mutation caused minimal disruption of GLP-1 
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binding affinity compared with much more significant impairment of GLP-1 mediated receptor 
activation [11].  
We have demonstrated and rationalised the importance of interactions between (i) Asp-15* 
and Arg-380, rotating TM7 and re-configuring ECL3 by pulling Glu-373 towards the ligand 
(Supplementary Figure S6A and S6B); (ii) Glu-21* and Arg-299, freeing Asp-372 and 
contributing further to the ECL3 reconfiguration (Supplementary Figure S6A and S6B); (iii) His-
7* with Glu-364 (stabilised by Arg-310) and with Glu-387 (stabilised by Lys-383) ± the movement 
of Glu-364 is possibly a critical characteristic of the movement and distortion of TM6 during the 
formation of the active state (Supplementary Figure S6C and S6D); and (iv) Glu-9* and Arg-190, 
freeing Gln-394 to stabilise the distortion in TM6 (Supplementary Figure S6E-G). By acting 
together, these various ligand-receptor interactions result in the stabilisation of an active receptor 
state in which TM6 moves to enable Gs to bind (Supplementary Figure S6G). Since N-terminally 
truncated GLP-1 can activate GLP-1R at high ligand concentrations in recombinant systems [26], 
it is likely that interactions (i) and (ii) are sufficient to generate the active state through the Asp-
15*/Glu-21*-mediated disruption of ECL3. However, clearly the additional interactions via His-7* 
make this transition substantially more efficient. 
In summary, we have demonstrated that fragments of several GLP-1R structures can be 
used to create stable and meaningful receptor models which can be simulated and analysed in order 
to answer important questions linking structure to function, and to propose agonist-mediated 
receptor activation mechanisms. 
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FIGURE LEGENDS 
 
FIGURE 1. 
Ribbon representations of 5VAI (A), 5UZ7 (B) and 5NX2 (C). Ligands are shown as sticks, TM6 
is shown in black, and the cavity space is shown for A and C as yellow. TM6 is highly distorted in 
5VAI and 5UZ7 and bends inwards at the centre to pack closely against the rest of the helical 
bundle. On the other hand, TM6 in 5NX2 is more regular and leaves an unusual cavity within the 
helical bundle that joins the cytoplasmic side to the extracellular binding pocket. 
 
FIGURE 2. 
Ribbon representations of the hybrid inactive (A) and hybrid active (B) starting models, with GLP-
1 shown in stick form in B. Regions derived from 5VEW (blue), 5NX2 (magenta) and 5VAI 
(green) are shown, although side chains were all converted to those of human wild type GLP-1R 
by SWISS-MODEL. Red regions were built by SWISS-MODEL as they were missing from the 
templates. C Root mean square deviation (RMSD) relative to the starting models for the 
simulations of the hybrid GLP-1R models - inactive (black, 385 ns) and active (red, 460 ns). D 
Distance between WKH&ĮDWRPVRI Arg-176 (TM2) and Arg-348 (TM6) ± these were 25.3 Å in the 
starting model for the active state (red) and 12.1 Å for the inactive state (black). 
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FIGURE 3 
Snaps shots of the inactive (blue) and active (green) models taken at 285 ns and 325 ns 
respectively. Stick representations have oxygens as red, nitrogens as blue, and hydrogen bonds as 
red dashes. A Overlay of both models showing how Arg-190 and Gln-394 interact in the inactive 
state, whereas in the active state Arg-190 instead interacts with Glu-9* of GLP-1 (yellow), freeing 
Gln-394 to move and interact elsewhere. B Gln-394 (yellow) in the active state provides an N-cap 
for the cytoplasmic half of TM6 at the carbonyl oxygen of Pro-358. C Arg-380 in the active 
receptor points towards the centre of the helical bundle and interacts with both Glu-373 and Asp-
15* of GLP-1. D Arg-380 in the inactive receptor points away from the helical bundle and 
interacts with Glu-373. The ligand-induced movement of Arg-380 may be responsible for 
rearranging ECL3. 
 
FIGURE 4 
The binding of GLP-1 (yellow) to the active GLP-1R model (snapshot at 325 ns). Stick 
representations have oxygens as red, nitrogens as blue, and hydrogen bonds as red dashes. The 
positively charged N-terminus of GLP-1 interacts with both Glu-364 and Glu-387, each of which 
additionally interact with Arg-310 and Lys-383 respectively. Since the N-terminus of GLP-1 is 
critical for the intrinsic activity, while the side chain of Arg-310 is essential for receptor activity, it 
may be that their ability to interact with Glu-364 in this manner is key to the conformational 
rearrangement of TM6. 
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The active state model of human GLP-1R was built from the GLP-1-bound/Gs-coupled rabbit 
GLP-1R cryo-EM structure 5VAI (green) and the thermo-stabilised mutated human GLP-1R x-ray 
structure 5NX2 (magenta) as depicted above and as described in Methods. Regions missing from 
the template were built by SWISS-MODEL (red). 
  27 
 
 
The inactive state model of human GLP-1R was built from thermo-stabilised inactive state human 
GLP-1R x-ray structure 5VEW (blue) and using the NTD from the thermo-stabilised mutated 
human GLP-1R x-ray structure 5NX2 (magenta) as depicted above and as described in Methods. 
Regions missing from the template were built by SWISS-MODEL (red). 
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The active state model of human GLP-1R shown in ribbon form (cyan) with the hydrophobic 
bilayer boundaries as predicted by OMP [17] as red space filled dummy atoms (left) and the POPC 
bilayer as built by CHARMM-GUI [18] in stick form (right). The carbon atoms (green) depict the 
hydrophobic region of the bilayer, while the phosphate, oxygen and nitrogen atoms (orange, red, 
blue) form the phospholipid head groups just outside the OMP boundary. Hence there was very 
good correlation between the OMP lipid boundary prediction and the POPC bilayer built by 
CHARM-GUI. 
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Comparison of 5NX2 (magenta with agonist as space-fill) and 5VAI (green). While Arg-380 and 
Lys-383 contact the ligand in 5NX2, as expected from mutagenesis data, in 5VAI they are 
displaced by 100° and face the lipid head-group region of the bilayer. Note that the Arg-380 side 
chain was built using the default conformation in PyMOL since the side chain is absent in the 
5VAI co-ordinates. 
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Comparison of the starting models of the inactive (blue) and active (green) states. The expected 
movement at the cytoplasmic end of TM6 to enable G protein binding is coupled with the 
downwards movement of the top part of TM6 and a distortion below His-363 at Gly-361. TM7 
bends at Gly-395 and the top part tilts towards TM6. It also twists to move Arg-380 and Lys-383 
into the ligand pocket, as expected from mutagenesis data. TM1 also tilts about a hinge and moves 
towards TM7. 
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Snapshots of inactive (blue) and active (green) models taken at 285 ns and 325 ns respectively. 
Stick representations have oxygens as red, nitrogens as blue, and hydrogen bonds as red dashes.  
A Overlay of both models showing how in the inactive ECL2 residue Arg-299 interacts with ECL-
3 residue Asp-372. In the active state, the ECL2-ECL3 interaction is replaced as Arg-299 interacts 
with Glu-292 and Glu-21* of GLP-1. B A number of other ECL2-ECL3 interactions are shown ± 
all these are absent in the active state as ECL3 is rearranged due to the conformational change in 
TM6. 
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Figure S6 
 
Snapshots of inactive (green) and active (cyan) models taken at 285 ns and 325 ns respectively. 
GLP-1 is shown as yellow. Stick representations have oxygens as red, nitrogens as blue, and 
hydrogen bonds as red dashes. Movements between sites in the inactive and active models are 
shown by arrows fading from green to cyan. 
  
A & B Arg-380 and Glu-373 interact and move towards the ligand, with Arg-380 interacting with 
Asp-15*. Arg-299 also moves towards the ligand and interacts with Glu-21* (and Glu-294). The 
Arg-299 to Asp-372 interaction seen in the inactive conformation is broken, as well as numerous 
other ECL2-ECL3 interactions. 
 
C & D Lys-383 and Glu-387 are distant in the inactive conformation but move together in the 
active state, with Glu-387 interacting directly with the N-terminal nitrogen of His-7*. The Arg-310 
to Glu-364 interaction observed in the inactive state is reformed in the active state but Glu-364 
moves towards the ligand and also interacts directly with the N-terminal nitrogen of His-7*. 
 
E & F Arg-190 to Gln-394 interaction seen in the inactive state is broken in the active state since 
Arg-190 moves to interact with Glu-9* of GLP-1. Gln-394 is then able to hydrogen bond to the 
carbonyl oxygen of Pro-358, possibly helping to stabilise the active conformation in which the 
lower part of TM6 moves outwards to enable Gs to bind (G). 
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